# NCT06800313 (NCT06800313)

> Study of HLD-0915 (JNJ-101556143) in Patients With Metastatic Prostate Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06800313
- Phase: PHASE1, PHASE2
- Status: RECRUITING
- Sponsor: Janssen Research & Development, LLC
- Conditions: Metastatic Prostate Cancer
- Interventions: JNJ-101556143 Formulation 1; JNJ-101556143 Formulation 2; JNJ-101556143 Formulation 3
- Enrollment: 190
- Primary outcome: Frequency of dose-limiting toxicities (DLTs)
- Primary outcome: Frequency and severity of AEs and abnormal ECG, laboratory and clinical changes since baseline
- Primary outcome: Phase 1 Part 2 (formulation exploration) relative bioavailability

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct06800313